Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

2.

Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.

Alaterre E, Raimbault S, Garcia JM, Rème T, Requirand G, Klein B, Moreaux J.

Cytometry B Clin Cytom. 2018 May;94(3):484-492. doi: 10.1002/cyto.b.21590. Epub 2017 Sep 19.

PMID:
28865180
3.

Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach.

Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J, Séverac D, Buée L, Rème T, Lehmann S.

Front Neurol. 2015 Aug 24;6:181. doi: 10.3389/fneur.2015.00181. eCollection 2015.

4.

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Hassen W, Kassambara A, Reme T, Sahota S, Seckinger A, Vincent L, Cartron G, Moreaux J, Hose D, Klein B.

Oncotarget. 2015 Mar 20;6(8):6431-47.

5.

GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells.

Kassambara A, Rème T, Jourdan M, Fest T, Hose D, Tarte K, Klein B.

PLoS Comput Biol. 2015 Jan 29;11(1):e1004077. doi: 10.1371/journal.pcbi.1004077. eCollection 2015 Jan.

6.

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.

Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Krämer A, Klein B, Raab MS.

Oncotarget. 2014 Nov 15;5(21):10237-50.

7.

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy.

Kassambara A, Gourzones-Dmitriev C, Sahota S, Rème T, Moreaux J, Goldschmidt H, Constantinou A, Pasero P, Hose D, Klein B.

Oncotarget. 2014 May 15;5(9):2487-98.

8.

In vitro infection of primary human hepatocytes by HCV-positive sera: insights on a highly relevant model.

Gondeau C, Briolotti P, Razafy F, Duret C, Rubbo PA, Helle F, Rème T, Ripault MP, Ducos J, Fabre JM, Ramos J, Pécheur EI, Larrey D, Maurel P, Daujat-Chavanieu M.

Gut. 2014 Sep;63(9):1490-500. doi: 10.1136/gutjnl-2013-304623. Epub 2013 Oct 23.

PMID:
24153249
9.

DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Gourzones-Dmitriev C, Kassambara A, Sahota S, Rème T, Moreaux J, Bourquard P, Hose D, Pasero P, Constantinou A, Klein B.

Cell Cycle. 2013 Sep 1;12(17):2760-73. doi: 10.4161/cc.25951. Epub 2013 Aug 9. Review.

10.

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.

Moreaux J, Reme T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B.

Br J Cancer. 2013 Aug 6;109(3):676-85. doi: 10.1038/bjc.2013.392. Epub 2013 Jul 18.

11.

A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas.

Rème T, Hugnot JP, Bièche I, Rigau V, Burel-Vandenbos F, Prévot V, Baroncini M, Fontaine D, Chevassus H, Vacher S, Lidereau R, Duffau H, Bauchet L, Joubert D.

PLoS One. 2013 Jun 21;8(6):e66574. doi: 10.1371/journal.pone.0066574. Print 2013.

12.

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Kassambara A, Schoenhals M, Moreaux J, Veyrune JL, Rème T, Goldschmidt H, Hose D, Klein B.

PLoS One. 2013 Apr 30;8(4):e62752. doi: 10.1371/journal.pone.0062752. Print 2013.

13.

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.

Witzens-Harig M, Hose D, Jünger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, Rème T, Gueckel B, Meißner T, Hundemer M, Ho AD, Rossi JF, Neben K, Bernhard H, Goldschmidt H, Klein B, Beckhove P.

Blood. 2013 May 30;121(22):4493-503. doi: 10.1182/blood-2012-05-429415. Epub 2013 Apr 19.

14.

Modeling risk stratification in human cancer.

Rème T, Hose D, Theillet C, Klein B.

Bioinformatics. 2013 May 1;29(9):1149-57. doi: 10.1093/bioinformatics/btt124. Epub 2013 Mar 14.

PMID:
23493321
15.

Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.

Moreaux J, Rème T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B.

Mol Cancer Ther. 2012 Dec;11(12):2685-92. doi: 10.1158/1535-7163.MCT-12-0721. Epub 2012 Oct 18.

16.

Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.

Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF, Goldschmidt H, Klein B.

PLoS One. 2012;7(7):e42161. doi: 10.1371/journal.pone.0042161. Epub 2012 Jul 31.

17.

Clinical and prognostic role of annexin A2 in multiple myeloma.

Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K, Rème T, Rösen-Wolff A, Jauch A, Schnettler R, Ewerbeck V, Goldschmidt H, Klein B, Hose D.

Blood. 2012 Aug 2;120(5):1087-94. doi: 10.1182/blood-2012-03-415588. Epub 2012 Jun 15.

18.

The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

Hose D, Seckinger A, Jauch A, Rème T, Moreaux J, Bertsch U, Neben K, Klein B, Goldschmidt H.

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:84-9.

19.

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B.

Haematologica. 2012 Apr;97(4):622-30. doi: 10.3324/haematol.2011.046821. Epub 2011 Nov 18.

20.

Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.

Meissner T, Seckinger A, Rème T, Hielscher T, Möhler T, Neben K, Goldschmidt H, Klein B, Hose D.

Clin Cancer Res. 2011 Dec 1;17(23):7240-7. doi: 10.1158/1078-0432.CCR-11-1628. Epub 2011 Oct 10.

21.

Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation.

Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Rème T, Bolloré K, Vendrell JP, Le Gallou S, Mourcin F, De Vos J, Kassambara A, Duperray C, Hose D, Fest T, Tarte K, Klein B.

J Immunol. 2011 Oct 15;187(8):3931-41. doi: 10.4049/jimmunol.1101230. Epub 2011 Sep 14.

22.

Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.

Bret C, Hose D, Reme T, Kassambara A, Seckinger A, Meissner T, Schved JF, Kanouni T, Goldschmidt H, Klein B.

Exp Hematol. 2011 May;39(5):546-557.e8. doi: 10.1016/j.exphem.2011.02.002. Epub 2011 Mar 3.

PMID:
21316416
23.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, Amiot M, Pellat-Deceunynck C.

Haematologica. 2011 Apr;96(4):574-82. doi: 10.3324/haematol.2010.033456. Epub 2010 Dec 20.

24.

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Moreaux J, Hose D, Kassambara A, Reme T, Moine P, Requirand G, Goldschmidt H, Klein B.

Blood. 2011 Jan 27;117(4):1280-90. doi: 10.1182/blood-2010-04-279760. Epub 2010 Nov 19.

25.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Möhler T, Rossi JF, Jauch A, Klein B, Goldschmidt H.

Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296. Epub 2010 Sep 30.

26.

MYEOV is a prognostic factor in multiple myeloma.

Moreaux J, Hose D, Bonnefond A, Reme T, Robert N, Goldschmidt H, Klein B.

Exp Hematol. 2010 Dec;38(12):1189-1198.e3. doi: 10.1016/j.exphem.2010.09.002. Epub 2010 Sep 18.

27.

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Mahtouk K, Moreaux J, Hose D, Rème T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H, Klein B.

BMC Cancer. 2010 May 13;10:198. doi: 10.1186/1471-2407-10-198.

28.

Recommendation for post-exposure prophylaxis after potential exposure to herpes b virus in Germany.

Remé T, Jentsch KD, Steinmann J, Kenner S, Straile U, Buse E, Sauerbrei A, Kaup FJ.

J Occup Med Toxicol. 2009 Nov 26;4:29. doi: 10.1186/1745-6673-4-29.

29.

Transcriptomic analysis identifies Foxo3A as a novel transcription factor regulating mesenchymal stem cell chrondrogenic differentiation.

Djouad F, Bony C, Canovas F, Fromigué O, Rème T, Jorgensen C, Noël D.

Cloning Stem Cells. 2009 Sep;11(3):407-16. doi: 10.1089/clo.2009.0013.

PMID:
19751111
30.

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B, Hose D.

Oncogene. 2009 Nov 5;28(44):3866-79. doi: 10.1038/onc.2009.257. Epub 2009 Aug 31.

31.

Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.

Condomines M, Hose D, Rème T, Requirand G, Hundemer M, Schoenhals M, Goldschmidt H, Klein B.

J Immunol. 2009 Jul 15;183(2):832-40. doi: 10.4049/jimmunol.0803298. Epub 2009 Jun 19.

32.

Induction of angiogenesis by normal and malignant plasma cells.

Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Rème T, De Vos J, Hundemer M, Condomines M, Bertsch U, Rossi JF, Jauch A, Klein B, Möhler T.

Blood. 2009 Jul 2;114(1):128-43. doi: 10.1182/blood-2008-10-184226. Epub 2009 Mar 18.

33.

Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells.

Bret C, Hose D, Reme T, Sprynski AC, Mahtouk K, Schved JF, Quittet P, Rossi JF, Goldschmidt H, Klein B.

Br J Haematol. 2009 May;145(3):350-68. doi: 10.1111/j.1365-2141.2009.07633.x. Epub 2009 Mar 2.

34.

Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients.

Haouzi D, Assou S, Mahmoud K, Tondeur S, Rème T, Hedon B, De Vos J, Hamamah S.

Hum Reprod. 2009 Jun;24(6):1436-45. doi: 10.1093/humrep/dep039. Epub 2009 Feb 26.

35.

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B.

Blood. 2009 May 7;113(19):4614-26. doi: 10.1182/blood-2008-07-170464. Epub 2009 Feb 18.

36.

Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Jourdan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J, Rossi JF, Hose D, Klein B.

Br J Haematol. 2009 Apr;145(1):45-58. doi: 10.1111/j.1365-2141.2008.07562.x. Epub 2009 Jan 8.

37.

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Hose D, Rème T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Krämer A, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Möhler T, Blake J, Zimmermann J, Klein B, Goldschmidt H.

Blood. 2009 Apr 30;113(18):4331-40. doi: 10.1182/blood-2008-09-178350. Epub 2009 Jan 26.

38.

Total fertilization failure and molecular abnormalities in metaphase II oocytes.

Gasca S, Reyftmann L, Pellestor F, Rème T, Assou S, Anahory T, Dechaud H, Klein B, De Vos J, Hamamah S.

Reprod Biomed Online. 2008 Dec;17(6):772-81.

PMID:
19079960
39.

A non-invasive test for assessing embryo potential by gene expression profiles of human cumulus cells: a proof of concept study.

Assou S, Haouzi D, Mahmoud K, Aouacheria A, Guillemin Y, Pantesco V, Rème T, Dechaud H, De Vos J, Hamamah S.

Mol Hum Reprod. 2008 Dec;14(12):711-9. doi: 10.1093/molehr/gan067. Epub 2008 Nov 21.

PMID:
19028806
40.

Identification of new biomarkers of human endometrial receptivity in the natural cycle.

Haouzi D, Mahmoud K, Fourar M, Bendhaou K, Dechaud H, De Vos J, Rème T, Dewailly D, Hamamah S.

Hum Reprod. 2009 Jan;24(1):198-205. doi: 10.1093/humrep/den360. Epub 2008 Oct 3.

PMID:
18835874
41.

A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments.

Rème T, Hose D, De Vos J, Vassal A, Poulain PO, Pantesco V, Goldschmidt H, Klein B.

BMC Bioinformatics. 2008 Jan 11;9:16. doi: 10.1186/1471-2105-9-16.

42.

Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.

Mahtouk K, Hose D, De Vos J, Moreaux J, Jourdan M, Rossi JF, Rème T, Goldschmidt H, Klein B.

Clin Cancer Res. 2007 Dec 15;13(24):7289-95. Review.

43.

CD200: a putative therapeutic target in cancer.

Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B.

Biochem Biophys Res Commun. 2008 Feb 1;366(1):117-22. Epub 2007 Dec 4.

PMID:
18060862
44.

In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.

Burjanadzé M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, Romagne F, Morel Y, Rossi JF, Klein B, Lu ZY.

Br J Haematol. 2007 Oct;139(2):206-16.

PMID:
17897296
45.

Transcriptome of retrovirally transduced CD8+ lymphocytes: influence of cell activation, transgene integration, and selection process.

Deschamps M, Robinet E, Certoux JM, Mercier P, Sauce D, De Vos J, Montcuquet N, Bonyhadi M, Rème T, Tiberghien P, Ferrand C.

Mol Immunol. 2008 Feb;45(4):1112-25. Epub 2007 Sep 10.

PMID:
17825913
46.

TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.

Moreaux J, Hose D, Jourdan M, Reme T, Hundemer M, Moos M, Robert N, Moine P, De Vos J, Goldschmidt H, Klein B.

Haematologica. 2007 Jun;92(6):803-11.

47.

Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.

Jourdan M, Moreaux J, Vos JD, Hose D, Mahtouk K, Abouladze M, Robert N, Baudard M, Rème T, Romanelli A, Goldschmidt H, Rossi JF, Dreano M, Klein B.

Br J Haematol. 2007 Jul;138(2):160-8. Epub 2007 Jun 3.

48.

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Rème T, Bourin P.

Leukemia. 2007 May;21(5):1079-88. Epub 2007 Mar 8.

49.

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, Moehler T, Rossi JF, Rème T, Goldschmidt H, Klein B.

Blood. 2007 Jun 1;109(11):4914-23. Epub 2007 Mar 5.

50.

Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.

Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Rème T, Goldschmidt H, Klein B.

J Immunol. 2007 Mar 1;178(5):3307-15.

Supplemental Content

Support Center